Daniel Wiśniewski, Izabela Uzar

The new generation uricosuric drugs, xanthine oxidase inhibitors, and combination therapy as options for gout pharmacotherapy – a review paper
2019-06-03

Due to adverse effects, uricosuric drugs have been withdrawn only for gout support. Xanthine oxidase inhibitors (XOI) took their place as the drugs of choice. Although they are easier to monitor and free from many side effects, they have a limited spectrum of associations within their own drug group and must be used with caution especially in older patients. New generation uricosuric medications, which can be used alone in patients resistant to XOI, have also been initiated for combination with XOI. The latest randomized trials seek to demonstrate the efficacy of combination medications instead of selective drug class assessments. Recently Il-1 blockers have been the subject of the analysis, too. Although their beneficial therapeutic effect in the gout exacerbation phase has been detected, the use of them has been limited by numerous contraindications and therefore comitted in the National Institute for Healt and Care Excellence recommendation. The aim of the scientific paper is to review the world literature on the evolution of gout pharmacology standards with particular emphasis on recently promoted combination therapy.

Keywords: new generation uricosuric drugs xanthine oxidase inhibitors –XOI combination therapy.

© Farm Pol, 2019, 75(5): 251–255